Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.36 |
| ▸ | ATM | Q13315 | 4/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15134073 | 0.76 | BRPF1 (0.41) | BRPF1TDP1PRKCIMAPTMEN1 | |
| SCHEMBL28165403 | 0.76 | L3MBTL1 (0.54) | TDP1L3MBTL1ATMMAPTKDM4E | |
| SCHEMBL19332384 | 0.73 | TDP1 (0.33) | TDP1L3MBTL1ATMKDM4EALDH1A1 | |
| SCHEMBL15133974 | 0.73 | MAPT (0.41) | BRPF1TDP1PRKCIMAPTMEN1 | |
| SCHEMBL351390 | 0.72 | KDM4E (0.50) | BRPF1TDP1L3MBTL1PRKCIMAPT | |
| SCHEMBL29433546 | 0.72 | KDM4E (0.50) | BRPF1TDP1L3MBTL1PRKCIMAPT | |
| SCHEMBL30349904 | 0.68 | NQO2 (0.61) | BRPF1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL17576254 | 0.68 | NQO2 (0.61) | BRPF1L3MBTL1MEN1KMT2AKDM4E | |
| SCHEMBL17657914 | 0.68 | PTGER4 (0.43) | TDP1L3MBTL1ATMMAPTKDM4E | |
| SCHEMBL19700082 | 0.68 | PTGER4 (0.47) | TDP1L3MBTL1ATMMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482368-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1404653-B1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PROD INC (US) | 2008-08-20 | — | — | EP | disclosed |
| US-7348355-B2 | Treating obesity with the Microsomal triglyceride transfer protein inhibitor (S) N-{2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl}-1-methyl-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carboxamido]-1H-indole-2-carboxamide and another lipid lowering agent such as a statin or fibrate | PFIZER INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2006-08-31 | — | — | US | disclosed |
| US-20050288335-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| US-6979692-B2 | such as (S)-1-ethyl-5-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-1H-indole-2-carboxylic acid-[2-[benzyl(methyl)amino]-2-oxo-1-phenylethyl]amide; for treatment of obesity and lipid disorders; diabetes | PFIZER INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-6949572-B2 | Triamide-substituted heterobicyclic compounds | PFIZER INC. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050080108-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2005-04-14 | — | — | US | disclosed |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC | 2004-05-06 | — | — | US | disclosed |
| US-6720351-B2 | 1H-INDOLE-2-CARBOXYLIC ACID (2-(BENZYL(METHYL)AMINO) -2-OXO-1-PHENYLETHYL)AMIDES; TRIAMIDE MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND APOLIPOPROTEIN B (APO B) INHIBITORS; OBESITY; ANTILIPEMIC AGENTS | PFIZER INC. | 2004-04-13 | — | — | US | disclosed |
| EP-1404653-A1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | Pfizer Products Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003002533-A1 | TRIAMIDE-SUBSTITUTED INDOLES, BENZOFURANES AND BENZOTHIOPHENES AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN (MTP) AND/OR APOLIPOPROTEIN B (APO B) SECRETION | PFIZER PRODUCTS INC. (US) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194772-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | BRPF1 884/4885TDP1 972/4885L3MBTL1 707/4885 |
| US-20040087625-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | BRPF1 1245/4885TDP1 652/4885L3MBTL1 881/4885 |
| US-20050288335-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | BRPF1 884/4885TDP1 972/4885L3MBTL1 707/4885 |
| US-20030187053-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | BRPF1 1245/4885TDP1 652/4885L3MBTL1 881/4885 |
| US-20050080108-A1 | Triamide-substituted heterobicyclic compounds | APOB, LIPC, MTTP | BRPF1 852/4885TDP1 896/4885L3MBTL1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.